Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:KLAC 20 January 2026 - 28 January 2026

KLA stock jumps nearly 5% as analysts lift targets ahead of Jan. 29 earnings

KLA stock jumps nearly 5% as analysts lift targets ahead of Jan. 29 earnings

KLA shares rose 4.8% to about $1,616 in after-hours trading Tuesday after Evercore ISI and Wolfe Research raised price targets ahead of Thursday’s earnings. The company projects fiscal Q2 revenue of $3.225 billion and non-GAAP EPS of $8.70, with Zacks’ consensus slightly higher. KLA warned U.S.-China trade tensions could cut sales by up to $350 million over the next five quarters.
28 January 2026
··
Lam Research stock jumps 7% as Evercore lifts target ahead of earnings

Lam Research stock jumps 7% as Evercore lifts target ahead of earnings

Lam Research shares jumped about 7% Tuesday to close at $238.46, ahead of its quarterly earnings report due Wednesday after the bell. Evercore ISI raised its price target on Lam to $241 from $170, maintaining an Outperform rating. After-hours trading showed little change in the stock. Investors are repositioning as Lam’s guidance often moves the broader chip equipment sector.
28 January 2026
·····
Applied Materials stock jumps nearly 5% as Micron’s Singapore expansion lifts chip-tool shares

Applied Materials stock jumps nearly 5% as Micron’s Singapore expansion lifts chip-tool shares

Applied Materials jumped 4.8% to $334.84 after Micron announced a $24 billion memory plant in Singapore, signaling higher chip equipment demand. Sector peers Lam Research, KLA, and ASML also advanced. Analysts expect enterprise SSD prices to surge as supply tightens. Investors await the Fed’s rate decision Wednesday and ASML’s earnings for clues on 2026 demand.
27 January 2026
······
KLA stock price firms into earnings week after Intel’s warning jolts chip names

KLA stock price firms into earnings week after Intel’s warning jolts chip names

KLA shares rose 0.9% to $1,512.78 Friday, recovering from Thursday’s decline as chip stocks swung on Intel’s weak outlook. New Street Research raised its KLA price target to $1,315 but kept a neutral rating. KLA will report fiscal Q2 results Jan. 29, with analysts expecting $8.78 per share on $3.26 billion revenue. Lam Research reports Jan. 28, setting the stage for the sector’s earnings cycle.
25 January 2026
··
KLA stock price whipsaws ahead of Jan. 29 earnings as Intel rattles chip sector

KLA stock price whipsaws ahead of Jan. 29 earnings as Intel rattles chip sector

KLA Corp shares closed Friday up 0.9% at $1,512.78 after swinging within a 4% range, ending about 4% below their 52-week high. Intel’s 17% drop rattled the semiconductor sector, sending the iShares Semiconductor ETF down 1.1%. KLA reports quarterly earnings Jan. 29 after market close, with investors watching for guidance on chipmaking demand and export controls.
24 January 2026
···
KLA stock price closes higher into weekend as KLAC heads for Fed decision and Jan. 29 earnings

KLA stock price closes higher into weekend as KLAC heads for Fed decision and Jan. 29 earnings

KLA shares rose 0.8% to $1,512.78 Friday, rebounding from session lows, while Applied Materials gained and Lam Research fell. Investors await the Federal Reserve’s Jan. 27-28 meeting and KLA’s earnings report on Jan. 29. The Dow dropped 0.58% and Intel slid 17% after a weak forecast. About 20% of S&P 500 companies report earnings next week.
24 January 2026
···
Applied Materials (AMAT) stock slides after hours as Feb. 12 earnings date nears

Applied Materials (AMAT) stock slides after hours as Feb. 12 earnings date nears

Applied Materials shares fell about 2% to $318.79 in after-hours trading Thursday after a volatile session, despite the S&P 500 and Dow both rising. The company set its fiscal first-quarter earnings release and call for Feb. 12. Options activity spiked near the $330 strike ahead of Friday’s expiration. Lam Research and KLA also declined, pressuring chip equipment stocks.
23 January 2026
····
Applied Materials stock rebounds after tariff scare fades; what to watch next for AMAT

Applied Materials stock rebounds after tariff scare fades; what to watch next for AMAT

Applied Materials rose 2.2% to $325.24 Wednesday, rebounding after Trump said he would delay tariffs tied to Greenland talks. Trading volume topped the 50-day average. Needham raised its price target to $390. The company warned of weaker China equipment spending in 2026 due to tighter U.S. export controls.
22 January 2026
·······
KLA stock tumbles into earnings week as Deutsche Bank lifts KLAC target

KLA stock tumbles into earnings week as Deutsche Bank lifts KLAC target

KLA shares fell 5.3% to $1,486.18 Tuesday, underperforming peers after President Trump threatened new tariffs on Europe. Deutsche Bank, Needham, and UBS all raised price targets but kept cautious ratings ahead of next week’s earnings. Trading volume surged to 1.7 million shares, well above average. Investors remain focused on 2026 chip-equipment spending guidance and potential tariff impacts.
21 January 2026
··
Lam Research stock swings on tariff jitters as UBS lifts target ahead of earnings

Lam Research stock swings on tariff jitters as UBS lifts target ahead of earnings

Lam Research shares closed down 0.25% Tuesday, holding near $222 in muted after-hours trading as tariff threats from President Trump pressured tech stocks. UBS raised its price target on Lam to $255, citing strong Q2 prospects. Lam’s earnings report is set for Jan. 28. Applied Materials and KLA fell more sharply, dropping 2.7% and 5.2% respectively.
21 January 2026
····
1 2 3 4 5 … 7

Stock Market Today

  • Novavax (NVAX) Stock Falls 1.23% Amid Upcoming Earnings Report
    March 20, 2026, 7:08 PM EDT. Novavax (NVAX) shares closed at $9.62, down 1.23%, outperforming the broader market declines as the S&P 500 fell 1.51%. Over the past month, Novavax gained 5.58%, surpassing the Medical sector's 7.54% loss. Investors await the company's financial results, expecting a substantial earnings per share (EPS) decline of 110.58% year-over-year to -$0.31 and revenues forecasted to fall 91.63% to $55.78 million. Full-year estimates also show significant drops. Despite this, the Zacks Consensus EPS estimate recently rose 47.68%, leading to a Zacks Rank of #3 (Hold) for Novavax. The Medical - Biomedical and Genetics industry ranks in the bottom 42% of all industries, reflecting sector challenges. Market watchers are advised to monitor updates closely as Novavax navigates these headwinds.
Go toTop